LearnDrugs.com
Musculoskeletal

Antigout Agents

High-yield Verified · Jul 2026

Prototype: allopurinol

Gout drugs split into acute-attack relievers and long-term urate-lowerers — using the wrong one at the wrong time backfires.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Gout — uric acid crystals in the joint

Gout happens when uric acid (the end-product of purine breakdown) builds up and forms sharp crystals in a joint — classically the big toe. The immune system attacks the crystals, causing a sudden, exquisitely painful, red, swollen joint (an acute gout attack). Over time, high uric acid also forms tophi and damages joints and kidneys.

That two-part disease needs two different drug strategies, and mixing them up is the classic error: calm the acute inflammation now, and lower uric acid for the long term — but *not* during an attack.

Two goals: quiet the acute inflammatory attack vs. lower uric acid long-term.

02 Acute vs long-term — and the timing trap

For an acute attack, the goal is anti-inflammatory: colchicine (best early in the attack), NSAIDs, or corticosteroids. Colchicine works by disrupting the neutrophils that attack the crystals — but it has a narrow margin, causing dose-limiting diarrhea/GI toxicity and, in overdose or renal/hepatic impairment, serious toxicity.

For the long term, the goal is to lower uric acid: allopurinol and febuxostat block xanthine oxidase (the enzyme that makes uric acid), while probenecid helps the kidney excrete more urate. The crucial timing rule: do not start (or stop) a urate-lowering drug during an acute attack — abruptly changing uric-acid levels can mobilize crystals and trigger/worsen a flare. Urate-lowering therapy is begun *after* the attack settles, often with colchicine/NSAID "cover."

03 Allopurinol’s serious risks

Allopurinol’s major danger is hypersensitivity — from rash up to Stevens-Johnson syndrome / toxic epidermal necrolysis and DRESS (higher risk with the **HLA-B*5801 allele). Any spreading rash means stop the drug. Allopurinol also dangerously raises levels of azathioprine and 6-mercaptopurine (both are metabolized by xanthine oxidase). Patients should push fluids** to prevent urate stones, and understand that a flare can occur early in therapy — that isn’t a reason to stop.

Allopurinol blocks xanthine oxidase (↓ uric acid) — but that same enzyme clears azathioprine/6-MP.

Drug names

Generic Brand
allopurinol Zyloprim
febuxostat Uloric
colchicine Colcrys
probenecid —

Indications

  • Acute gout attack (colchicine, NSAIDs, corticosteroids)
  • Long-term urate lowering / chronic gout & tophi (allopurinol, febuxostat, probenecid)
  • Tumor-lysis-syndrome prevention (allopurinol/rasburicase)

Mechanism of action

Acute agents are anti-inflammatory (colchicine inhibits neutrophil microtubules/migration; NSAIDs and steroids reduce inflammation). Urate-lowering agents reduce uric acid: allopurinol/febuxostat inhibit xanthine oxidase (↓ production); probenecid is uricosuric (↑ renal excretion).

In plain terms
Some gout drugs calm the acute inflammation; others lower the uric acid that causes gout in the first place.

Therapeutic effects — what you'll see working

Success is a settled acute attack and, long-term, a uric acid low enough to prevent recurrence and dissolve tophi (often target < 6 mg/dL). The timing rule — don’t start urate-lowering therapy mid-attack — is the key nursing point.

Acute attack relief Lowered uric acid (long-term)
Acute attack relief
Colchicine/NSAIDs/steroids reduce the crystal-driven inflammation, relieving the painful, swollen joint.
Lowered uric acid (long-term)
Xanthine-oxidase inhibitors or uricosurics keep uric acid low, preventing attacks and shrinking tophi over months.

Adverse effects

Colchicine’s issue is GI/narrow-margin toxicity; the urate-lowerers’ concern is triggering flares on initiation and (allopurinol) hypersensitivity/interactions.

Caution: Common
Colchicine: diarrhea, nausea, cramping. Allopurinol/febuxostat: early flare on initiation, GI upset, rash. Probenecid: GI upset.
Colchicine diarrhea is dose-limiting. An early flare when starting urate-lowering therapy is expected — cover with colchicine/NSAID and continue.
Warning: Serious Hold & notify
Allopurinol hypersensitivity (SJS/TEN, DRESS); allopurinol–azathioprine/6-MP interaction; colchicine toxicity (marrow suppression, esp. renal/hepatic impairment or CYP3A4/P-gp inhibitors); urate stones.
Stop allopurinol for any spreading rash (SJS/TEN risk, esp. HLA-B*5801). Allopurinol markedly raises azathioprine/6-MP toxicity. Colchicine is dangerous in renal/hepatic impairment and with strong CYP3A4/P-glycoprotein inhibitors.

Contraindications

The cautions are the timing rule, the allopurinol interactions/hypersensitivity, and colchicine in organ impairment.

Starting/stopping urate-lowering therapy during an acute attack
Shifting uric-acid levels mobilizes crystals and can trigger or worsen a flare.
Allopurinol with azathioprine/6-mercaptopurine (without dose reduction)
Xanthine-oxidase inhibition raises their levels to dangerous marrow-toxic ranges.
Colchicine in significant renal/hepatic impairment or with strong CYP3A4/P-gp inhibitors use caution
Reduced clearance causes severe colchicine toxicity.

When to hold

Assess before giving — these findings mean hold the dose and act.

Which drug for which phase
Allopurinol = chronic/urate-lowering, not for an acute attack; colchicine = acute. Don’t start urate-lowering therapy mid-attack, and increase fluids to prevent urate stones.
Allopurinol — any spreading rash (SJS/TEN, DRESS)
Hold and stop allopurinol, notify the prescriber — a spreading rash may herald Stevens-Johnson syndrome.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Timing & monitoring
Do not initiate allopurinol/febuxostat during an acute attack; when starting, expect an early flare and continue.
Why: Abrupt urate shifts trigger flares; stopping at the first flare defeats long-term control.
Stop allopurinol for any rash; screen for azathioprine/6-MP use and monitor uric acid and renal function.
Why: Rash may herald SJS/TEN; the azathioprine interaction is potentially fatal.
Patient teaching
Push fluids, limit alcohol/purine-rich foods, and take urate-lowering therapy daily and long-term even when symptom-free.
Why: Fluids prevent urate stones; consistent therapy keeps uric acid low and prevents attacks.
For colchicine, stop and report severe diarrhea/vomiting or muscle weakness.
Why: These are early signs of colchicine toxicity.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.